Our data suggest that haprolid treatment has great antitumor activity in HCC through dual inhibition of Rb/E2F and Akt/mTOR pathways; thus, it may be a new and promising candidate for systemic treatment of HCC. The gene discussed is AKT1; the disease is hepatocellular carcinoma.